On Thursday, Shares of ONEOK, Inc. (NYSE:OKE), gained 1.02% to $38.69.
ONEOK, declared a quarterly dividend of 60.5 cents per share, effective for the second quarter 2015, payable Aug. 14, 2015, to shareholders of record at the close of business Aug. 3, 2015.
The dividend remains unchanged from the previous quarter and represents a 5 percent enhance contrast with the second quarter 2014.
ONEOK, Inc., through its general partner interests in ONEOK Partners, L.P., engages in the gathering, processing, storage, and transportation of natural gas in the United States.
Shares of Avis Budget Group Inc. (NASDAQ:CAR), declined -2.70% to $41.13, during its last trading session.
Avis Car Rental, unveiled a new way for members of Avis Preferred, the Company’s express rental program, to get rewarded for renting from Avis. Now, Avis Preferred members are eligible to earn Avis Preferred Points — one point for every dollar they spend on vehicle rentals and two points for every dollar they spend on optional products such as GPS, satellite radio and child safety seat rentals. Earned points can be redeemed for complimentary Avis rental days, upgrades and select optional products.
In addition, when Avis Preferred members complete 12 rentals or spend $5,000 on base rentals plus optional products within a calendar year, they will automatically earn Avis Preferred Plus status. With Avis Preferred Plus, members receive a one car-class complimentary upgrade whenever accessible, access to a special Avis Preferred Plus reservation/support telephone number and exclusive monthly email offers. Those with Avis Preferred Plus status will also earn 25 to 50 percent more points for every dollar they spend.
Avis Budget Group, Inc., together with its auxiliaries, provides car and truck rentals, car sharing, and ancillary services to businesses and consumers worldwide. The company has three segments: North America, International, and Truck Rental.
At the end of Thursday’s trade, Shares of Cara Therapeutics Inc (NASDAQ:CARA), gained 19.89% to $18.99.
Cara Therapeutics declared statistically noteworthy topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis. There are presently no approved products in the United States for the condition.
“These results demonstrate the potential of our lead candidate CR845 to address an additional indication of noteworthy unmet need beyond our lead I.V. CR845 program in acute pain,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “With this encouraging data, we plan to engage the FDA in a formal meeting to guide the structure of a potential Phase 3 pivotal trial, which we would expect to start in 2016.”
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.
Finally, Windstream Holdings, Inc. (NASDAQ:WIN), ended its last trade with -3.57% loss, and closed at $4.86.
Windstream, will hold a conference call at 7:30 a.m. CDT on Aug. 6 to review the company’s second-quarter earnings results.
A replay of the call will be accessible starting at 10:30 a.m. CDT on Aug. 6 and ending at midnight on Aug. 13. The replay can be accessed by dialing 1-855-859-2056, conference ID 82120098.
Windstream Holdings, Inc. provides communications and technology solutions in the United States. It offers managed services and cloud computing services to businesses, in addition to broadband, voice, and video services to consumers primarily in rural markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
